The combination of DEBs and RFA "has potential to become the standard approach" for certain liver cancers.

— Riccardo Leoncioni, MD, an interventional radiologist from Italy, describing AngioDynamics' LC Beads drug-delivery product, "Fledgling subspecialty shows growing interest, new tech," pp. 1, 6.